ALMS vs. DNLI
ALMS (Alumis Inc) and DNLI (Denali Therapeutics Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past year, ALMS returned 482.03% vs 41.13% for DNLI. At a 0.22 correlation, their price movements are largely independent.
Performance
ALMS vs. DNLI - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ALMS achieves a 105.74% return, which is significantly higher than DNLI's 19.08% return.
ALMS
- 1D
- 0.20%
- 1M
- -20.48%
- YTD
- 105.74%
- 6M
- 156.12%
- 1Y
- 482.03%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
DNLI
- 1D
- 1.60%
- 1M
- 5.30%
- YTD
- 19.08%
- 6M
- 3.47%
- 1Y
- 41.13%
- 3Y*
- -14.56%
- 5Y*
- -21.18%
- 10Y*
- —
ALMS vs. DNLI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
ALMS Alumis Inc | 105.74% | 24.17% | -40.90% |
DNLI Denali Therapeutics Inc. | 19.08% | -18.99% | -12.23% |
Correlation
The correlation between ALMS and DNLI is 0.31, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.31 |
Correlation (All Time) Calculated using the full available price history since Jul 1, 2024 | 0.22 |
Fundamentals
ALMS:
$2.51B
DNLI:
$3.67B
ALMS:
-$2.31
DNLI:
-$2.88
ALMS:
4.43
DNLI:
3.96
ALMS:
$8.40M
DNLI:
$0.00
ALMS:
$5.79M
DNLI:
-$2.87M
ALMS:
-$411.89M
DNLI:
-$526.60M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ALMS vs. DNLI — Risk / Return Rank
ALMS
DNLI
ALMS vs. DNLI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Alumis Inc (ALMS) and Denali Therapeutics Inc. (DNLI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ALMS | DNLI | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 4.01 | 0.73 | +3.28 |
Sortino ratioReturn per unit of downside risk | 5.49 | 1.38 | +4.11 |
Omega ratioGain probability vs. loss probability | 1.68 | 1.16 | +0.51 |
Calmar ratioReturn relative to maximum drawdown | 14.66 | 2.02 | +12.65 |
Martin ratioReturn relative to average drawdown | 37.24 | 4.01 | +33.23 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| ALMS | DNLI | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 4.01 | 0.73 | +3.28 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | -0.34 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.21 | -0.02 | +0.22 |
Drawdowns
ALMS vs. DNLI - Drawdown Comparison
The maximum ALMS drawdown since its inception was -78.95%, smaller than the maximum DNLI drawdown of -87.74%. Use the drawdown chart below to compare losses from any high point for ALMS and DNLI.
Loading charts...
Drawdown Indicators
| ALMS | DNLI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -78.95% | -87.74% | +8.79% |
Max Drawdown (1Y)Largest decline over 1 year | -33.16% | -20.49% | -12.67% |
Max Drawdown (3Y)Largest decline over 3 years | — | -65.20% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -85.38% | — |
Current DrawdownCurrent decline from peak | -33.02% | -78.99% | +45.97% |
Average DrawdownAverage peak-to-trough decline | -38.16% | -51.47% | +13.31% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.03% | 10.29% | +2.74% |
Volatility
ALMS vs. DNLI - Volatility Comparison
Alumis Inc (ALMS) has a higher volatility of 16.64% compared to Denali Therapeutics Inc. (DNLI) at 15.16%. This indicates that ALMS's price experiences larger fluctuations and is considered to be riskier than DNLI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ALMS | DNLI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 16.64% | 15.16% | +1.48% |
Volatility (6M)Calculated over the trailing 6-month period | 89.27% | 42.44% | +46.83% |
Volatility (1Y)Calculated over the trailing 1-year period | 121.24% | 56.73% | +64.51% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 116.89% | 62.52% | +54.37% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 116.89% | 65.21% | +51.68% |
Dividends
ALMS vs. DNLI - Dividend Comparison
Neither ALMS nor DNLI has paid dividends to shareholders.
Financials
ALMS vs. DNLI - Financials Comparison
This section allows you to compare key financial metrics between Alumis Inc and Denali Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ALMS and DNLI have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ALMS has higher volatility (16.64%) compared to DNLI (15.16%). In terms of maximum drawdown, ALMS dropped -78.95% vs DNLI's -87.74%.
ALMS currently has the higher Sharpe Ratio (4.01 vs 0.73), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ALMS and DNLI
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer